Metis Precision Medicine
James Hughes is currently the Head of Technology Transfer at Candiolo Cancer Institute IRCCS, where James leads the innovation process to create products in the life science field. James is also the Co-Founder of Metis Precision Medicine, specializing in immuno-oncology therapies. With a background in research and development, James has extensive experience in project leadership, research business development, and knowledge transfer within the medical and biotechnology industries.
This person is not in any teams
Metis Precision Medicine
Metis Precision Medicine is a B-Corp founded with the vision of bringing powerful cancer therapies to patients in need. Metis owns the intellectual property of a suite of anti-Met monoclonal antibodies (mAbs), with different and unique mechanisms of action, and is currently seeking investors, biotech or pharmaceutical companies interested inacquiring the relevant platform technology on a global basis.